Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PRNP | P04156 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648993 | 0.79 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL3310894 | 0.66 | MEN1 (0.45) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL31598494 | 0.65 | MEN1 (0.44) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL23457512 | 0.65 | HTR2A (0.40) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL31494678 | 0.64 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL4056257 | 0.64 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL10430601 | 0.64 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL11641022 | 0.64 | NPC1 (0.48) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL3869454 | 0.64 | KMT2A (0.41) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL28701448 | 0.64 | CCNA2 (0.45) | ADRA2AADRA2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| EP-1725526-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | Applied Research Systems ARS Holding N.V. (AN) | 2006-11-29 | — | — | EP | disclosed |
| US-20060189583-A1 | Aryl dicarboxamides | MERCK SERONO SA (CH) | 2006-08-24 | — | — | US | disclosed |
| WO-2005082848-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | disclosed |
| EP-1084119-B1 | AROMATIC AMINE DERIVATIVES AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189583-A1 | Aryl dicarboxamides | GPR119, PTPRS, ECHS1 | ADRA2A 2953/4885ADRA2B 3293/4885ADRA2C 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.